|Dr. Gene G. Kinney Ph.D.||Pres, CEO & Director||1.02M||N/A||1969|
|Mr. Tran B. Nguyen M.B.A.||CFO & Chief Strategy Officer||745.35k||N/A||1974|
|Mr. Brandon S. Smith||Chief Operating Officer||648.34k||N/A||1975|
|Ms. Carol D. Karp||Chief Regulatory Officer||679.3k||N/A||1953|
|Dr. Hideki Garren M.D., Ph.D.||Chief Medical Officer||859.64k||N/A||1965|
|Ms. Karin L. Walker CPA, CPA||Chief Accounting Officer & Controller||N/A||N/A||1963|
|Dr. Wagner M. Zago||Chief Scientific Officer||N/A||N/A||1973|
|Ms. Jennifer Zibuda||Director of Investor Relations & Communication||N/A||N/A||N/A|
|Mr. Michael J. Malecek||Chief Legal Officer||N/A||N/A||1966|
|Dr. Radhika Tripuraneni M.P.H., M.D.||Chief Devel. Officer||N/A||N/A||1980|
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Prothena Corporation plc’s ISS governance QualityScore as of 1 May 2022 is 5. The pillar scores are Audit: 9; Board: 4; Shareholder rights: 4; Compensation: 6.